Brain drug delivery systems for neurodegenerative disorders

Current Pharmaceutical Biotechnology

Volumn 13, Issue 12, 2012, Pages 2388-2402

  Garbayo, E ^a,b   Ansorena, E ^c   Blanco Prieto, M J ^d  

^a INSERM   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Blood brain barrier; Drug delivery systems; Neurodegenerative disorders; Stereotactic surgery

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETHANECHOL; CARBIDOPA; DOPAMINE; LACTOFERRIN; LEVODOPA; LIATERMIN; LIPOSOME; NANOMATERIAL; NANOPARTICLE; NEUROTROPHIC FACTOR; NORADRENALIN; PLASMID DNA; POLYSORBATE 80; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RECOMBINANT NERVE GROWTH FACTOR; RECOMBINANT PROTEIN; RECOMBINANT VASCULOTROPIN; RIVASTIGMINE; SINGLE WALLED NANOTUBE; SOLID LIPID NANOPARTICLE; TACRINE; TEMPOL;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; DEGENERATIVE DISEASE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MEGADOSE; GASTROINTESTINAL SYMPTOM; GEL; GENE THERAPY; HUMAN; HUNTINGTON CHOREA; IMPLANT; LIVER DISEASE; MICELLE; MICROEMULSION; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PARTICLE SIZE;

ANIMALS; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; NEURODEGENERATIVE DISEASES; PHARMACEUTICAL PREPARATIONS;

EID: 84867709316     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112803341761     Document Type: Article

References (134)

1. Palmer, A.M.; The role of the blood-CNS barrier in CNS disorders and their treatment. Neurobiol. Dis., 2010, 37(1), 3-12.
2. Pasha, S.; Gupta, K. Various drug delivery approaches to the central nervous system. Expert Opin. Drug Deliv., 2010, 7(1), 113-135.
3. Gabathuler, R. Blood-brain barrier transport of drugs for the treatment of brain diseases. CNS Neurol. Disord. Drug Targets, 2009, 8(3), 195-204.
4. Patel, M.M.; Goyal, B.R.; Bhadada, S.V.; Bhatt, J.S.; Amin, A.F. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs., 2009, 23(1), 35-58.
5. Kaur, I.P.; Bhandari, R.; Bhandari, S.; Kakkar, V. Potential of solid lipid nanoparticles in brain targeting. J. Control. Release, 2008, 127(2), 97-109.
6. Di Stefano, A.; Sozio, P.; Iannitelli, A.; Cerasa, L.S. New drug delivery strategies for improved Parkinson's disease therapy. Expert Opin. Drug Deliv., 2009, 6(4), 389-404.
7. Domb, A.J. Polymeric carriers for regional drug therapy. Mol. Med. Today, 1995, 1(3), 134-139.
8. Begley, D.J., Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther., 2004, 104(1), 29-45.
9. Shive, M.S.; Anderson, J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev., 1997, 28(1), 5-24.
10. Athanasiou, K.A.; Niederauer, G.G.; Agrawal, C.M. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials, 1996, 17(2), 93-102.
11. Lian, T.; Ho, R. J. Trends and developments in liposome drug delivery systems. J. Pharm. Sci., 2001, 90(6), 667-680.
12. Adams, M. L.; Lavasanifar, A.; Kwon, G. S. Amphiphilic block copolymers for drug delivery. J. Pharm. Sci., 2003, 92(7), 1343-1355.
13. Na, M.; Yiyun, C.; Tongwen, X.; Yang, D.; Xiaomin, W.; Zhenwei, L.; Zhichao, C.; Guanyi, H.; Yunyu, S.; Longping, W. Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by in vitro and in vivo studies. Eur. J. Med. Chem., 2006, 41(5), 670-674.
14. Garcia-Garcia, E.; Andrieux, K.; Gil, S.; Couvreur, P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int. J. Pharm., 2005, 298(2), 274-292.
15. Lockman, P.R.; Mumper, R.J.; Khan, M.A.; Allen, D.D. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev. Ind. Pharm., 2002, 28(1), 1-13.
16. Kreuter, J.; Ramge, P.; Petrov, V.; Hamm, S.; Gelperina, S. E.; Engelhardt, B.; Alyautdin, R.; von Briesen, H.; Begley, D. J. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res., 2003, 20(3), 409-416.
17. Voinea, M.; Simionescu, M. Designing of 'intelligent' liposomes for efficient delivery of drugs. J. Cell Mol. Med., 2002, 6(4), 465-474.
18. Schnyder, A.; Huwyler, J. Drug transport to brain with targeted liposomes. NeuroRx., 2005, 2, (1), 99-107.
19. Misra, A.; Ganesh, S.; Shahiwala, A.; Shah, S. P. Drug delivery to the central nervous system: a review. J. Pharm. Pharm. Sci., 2003, 6(2), 252-273.
20. Allen, T. M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci., 1994, 15(7), 215-220.
21. Pardridge, W.M.; Boado, R.J.; Black, K.L.; Cancilla, P.A. Bloodbrain barrier and new approaches to brain drug delivery. West J. Med., 1992, 156(3), 281-286.
22. Vinogradov, S.V.; Batrakova, E.V.; Kabanov, A.V. Nanogels for oligonucleotide delivery to the brain. Bioconjug. Chem., 2004, 15(1), 50-60.
23. Vinogradov, S.V. Colloidal microgels in drug delivery applications. Curr. Pharm. Des., 2006, 12(36), 4703-4712.
24. Brioschi, A.; Zenga, F.; Zara, G.P.; Gasco, M.R.; Ducati, A.; Mauro, A. Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors? Neurol. Res., 2007, 29(3), 324-330.
25. Chattopadhyay, N.; Zastre, J.; Wong, H.L.; Wu, X.Y.; Bendayan, R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm. Res., 2008, 25(10), 2262-2271.
26. Gilmore, J.L.; Yi, X.; Quan, L.; Kabanov, A.V. Novel nanomaterials for clinical neuroscience. J. Neuroimmune Pharmacol., 2008, 3(2), 83-94.
27. Modi, G.; Pillay, V.; Choonara, Y. E. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann. N. Y. Acad. Sci., 2010, 1184, 154-172.
28. Liu, L.; Venkatraman, S.S.; Yang, Y.Y.; Guo, K.; Lu, J.; He, B.; Moochhala, S.; Kan, L. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier. Biopolymers, 2008, 90(5), 617-623.
29. Papa, S.M.; Engber, T. M.; Kask, A. M.; Chase, T. N. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res., 1994, 662(1-2), 69-74.
30. Fahn, S. Is levodopa toxic? Neurology, 1996, 47 (6 Suppl 3), S184-195.
31. Arica, B.; Kas, H. S.; Moghdam, A.; Akalan, N.; Hincal, A. A. Carbidopa/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats. J. Control. Release, 2005, 102(3), 689-697.
32. Mc Rae, A.; Dahlstrom, A. Transmitter-loaded polymeric microspheres induce regrowth of dopaminergic nerve terminals in striata of rats with 6-OH-DA induced parkinsonism. Neurochem. Int., 1994, 25(1), 27-33.
33. Lin, L.F.; Doherty, D.H.; Lile, J.D.; Bektesh, S.; Collins, F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science, 1993, 260(5111), 1130-1132.
34. Grondin, R.; Gash, D.M. Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease. J. Neurol., 1998, 245(11 Suppl 3), P35-42.
35. Patel, N.K.; Bunnage, M.; Plaha, P.; Svendsen, C.N.; Heywood, P.; Gill, S.S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol., 2005, 57(2), 298-302.
36. Lang, A.E.; Gill, S.; Patel, N.K.; Lozano, A.; Nutt, J.G.; Penn, R.; Brooks, D.J.; Hotton, G.; Moro, E.; Heywood, P.; Brodsky, M.A.; Burchiel, K.; Kelly, P.; Dalvi, A.; Scott, B.; Stacy, M.; Turner, D.; Wooten, V.G.; Elias, W.J.; Laws, E.R.; Dhawan, V.; Stoessl, A.J.; Matcham, J.; Coffey, R.J.; Traub, M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol., 2006, 59(3), 459-466.
37. Gill, S.S.; Patel, N.K.; Hotton, G.R.; O'Sullivan, K.; McCarter, R.; Bunnage, M.; Brooks, D.J.; Svendsen, C. N.; Heywood, P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med., 2003, 9(5), 589-595.
38. Slevin, J.T.; Gerhardt, G.A.; Smith, C.D.; Gash, D.M.; Kryscio, R.; Young, B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg., 2005, 102(2), 216-222.
39. Palfi, S.; Leventhal, L.; Chu, Y.; Ma, S.Y.; Emborg, M.; Bakay, R.; Deglon, N.; Hantraye, P.; Aebischer, P.; Kordower, J.H. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J. Neurosc., 2002, 22(12), 4942-4954.
40. Kordower, J.H.; Emborg, M.E.; Bloch, J.; Ma, S.Y.; Chu, Y.; Leventhal, L.; McBride, J.; Chen, E.Y.; Palfi, S.; Roitberg, B.Z.; Brown, W.D.; Holden, J.E.; Pyzalski, R.; Taylor, M.D.; Carvey, P.; Ling, Z.; Trono, D.; Hantraye, P.; Deglon, N.; Aebischer, P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science, 2000, 290(5492), 767-773.
41. Garbayo, E.; Montero-Menei, C.N.; Ansorena, E.; Lanciego, J.L.; Aymerich, M.S.; Blanco-Prieto, M.J. Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease. J. Control. Release., 2009, 135(2), 119-126.
42. Jollivet, C.; Aubert-Pouessel, A.; Clavreul, A.; Venier-Julienne, M.C.; Remy, S.; Montero-Menei, C.N.; Benoit, J.P.; Menei, P. Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. Biomaterials, 2004, 25(5), 933-942.
43. Jollivet, C.; Aubert-Pouessel, A.; Clavreul, A.; Venier-Julienne, M.C.; Montero-Menei, C.N.; Benoit, J.P.; Menei, P. Long-term effect of intra-striatal glial cell line-derived neurotrophic factorreleasing microspheres in a partial rat model of Parkinson's disease. Neurosci. Lett., 2004, 356(3), 207-210.
44. Garbayo, E.; Ansorena, E.; Lanciego, J.L.; Aymerich, M.S.; Blanco-Prieto, M.J. Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres. Eur. J. Pharm. Biopharm., 2008, 69(3), 844-851.
45. Garbayo, E.; Ansorena, E.; Lanciego, J.L.; Aymerich, M.S.; Blanco-Prieto, M.J. Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor. Int. J. Pharm., 2007, 344(1-2), 9-15.
46. Menei, P.; Montero-Menei, C.; Venier, M. C.; Benoit, J. P. Drug delivery into the brain using poly(lactide-co-glycolide) microspheres. Expert. Opin. Drug Deliv., 2005, 2(2), 363-376.
47. Ansorena, E.; Garbayo, E.; Lanciego, J.L.; Aymerich, M.S.; Blanco-Prieto, M.J. Production of highly pure human glycosylated GDNF in a mammalian cell line. Int. J. Pharm., 2010, 385(1-2), 6-11.
48. Tatard, V.M.; Venier-Julienne, M.C.; Benoit, J.P.; Menei, P.; Montero-Menei, C. N. In vivo evaluation of pharmacologically active microcarriers releasing nerve growth factor and conveying PC12 cells. Cell Transplant., 2004, 13(5), 573-583.
49. Tatard, V.M.; Sindji, L.; Branton, J.G.; Aubert-Pouessel, A.; Colleau, J.; Benoit, J. P.; Montero-Menei, C. N. Pharmacologically active microcarriers releasing glial cell line-derived neurotrophic factor: Survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats. Biomaterials., 2007, 28(11), 1978-1988.
50. Pillay, S.; Pillay, V.; Choonara, Y.E.; Naidoo, D.; Khan, R.A.; du Toit, L. C.; Ndesendo, V.M.; Modi, G.; Danckwerts, M.P.; Iyuke, S.E. Design, biometric simulation and optimization of a nanoenabled scaffold device for enhanced delivery of dopamine to the brain. Int. J. Pharm., 2009, 382(1-2), 277-290.
51. Kurakhmaeva, K.B.; Voronina, T.A.; Kapica, I.G.; Kreuter, J.; Nerobkova, L.N.; Seredenin, S.B.; Balabanian, V.Y.; Alyautdin, R.N. Antiparkinsonian effect of nerve growth factor adsorbed on polybutylcyanoacrylate nanoparticles coated with polysorbate-80. Bull Exp. Biol. Med., 2008, 145(2), 259-262.
52. Kurakhmaeva, K.B.; Djindjikhashvili, I.A.; Petrov, V.E.; Balabanyan, V.U.; Voronina, T.A.; Trofimov, S.S.; Kreuter, J.; Gelperina, S.; Begley, D.; Alyautdin, R.N. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J. Drug Target, 2009, 17(8), 564-574.
53. Carroll, R.T.; Bhatia, D.; Geldenhuys, W.; Bhatia, R.; Miladore, N.; Bishayee, A.; Sutariya, V. Brain-targeted delivery of Tempolloaded nanoparticles for neurological disorders. J. Drug Target, 2010, 18(9),665-674.
54. Dass, B.; Kordower, J.H. Gene therapy approaches for the treatment of Parkinson's disease. Handb. Clin. Neurol., 2007, 84, 291-304.
55. Suk, J.S.; Suh, J.; Choy, K.; Lai, S. K.; Fu, J.; Hanes, J. Gene delivery to differentiated neurotypic cells with RGD and HIV Tat peptide functionalized polymeric nanoparticles. Biomaterials, 2006, 27(29), 5143-5150.
56. Huang, R.; Ke, W.; Liu, Y.; Wu, D.; Feng, L.; Jiang, C.; Pei, Y. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J. Neurol. Sci., 2010, 290(1-2), 123-130.
57. Huang, R.; Han, L.; Li, J.; Ren, F.; Ke, W.; Jiang, C.; Pei, Y. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. J. Gene Med., 2009, 11(9), 754-763.
58. Huang, R.; Ke, W.; Han, L.; Liu, Y.; Shao, K.; Jiang, C.; Pei, Y. Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo. Brain Res. Bull., 2010, 81(6), 600-604.
59. Yurek, D.M.; Flectcher, A.M.; Kowalczyk, T.H.; Padegimas, L.; Cooper, M.J. Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons. Cell Transplant., 2009, 18(10), 1183-1196.
60. Bharali, D.J.; Klejbor, I.; Stachowiak, E.K.; Dutta, P.; Roy, I.; Kaur, N.; Bergey, E.J.; Prasad, P.N.; Stachowiak, M.K. Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc. Natl. Acad. Sci. USA, 2005, 102(32), 11539-11544.
61. Klejbor, I.; Stachowiak, E.K.; Bharali, D.J.; Roy, I.; Spodnik, I.; Morys, J.; Bergey, E.J.; Prasad, P.N.; Stachowiak, M. K. ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology. J. Neurosci. Methods., 2007, 165(2), 230-243.
62. Pardridge, W. M. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. NeuroRx., 2005, 2(1), 129-138.
63. Di Stefano, A.; Carafa, M.; Sozio, P.; Pinnen, F.; Braghiroli, D.; Orlando, G.; Cannazza, G.; Ricciutelli, M.; Marianecci, C.; Santucci, E. Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations. J. Control. Release, 2004, 99(2), 293-300.
64. Blennow, K.; de Leon, M. J.; Zetterberg, H. Alzheimer's disease. Lancet, 2006, 368(9533), 387-403.
65. Selkoe, D.J. The origins of Alzheimer disease: a is for amyloid. JAMA, 2000, 283(12), 1615-1617.
66. Spillantini, M. G.; Goedert, M. Tau protein pathology in neurodegenerative diseases. Trends. Neurosci., 1998, 21(10), 428-433.
67. Cummings, J.L. Alzheimer's disease. N. Engl. J. Med., 2004, 351(1), 56-67.
68. Evans, D.A. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q., 1990, 68(2), 267-289.
69. 3rd.; Gross, A.; Grady, M.S.; Langer, R.S.; Mathiowitz, E.; Winn, H.R.; Mayberg, M.R. Intracerebral drug delivery in rats with lesion-induced memory deficits. J. Neurosurg., 1989, 71 (1), 105-112.
70. Hefti, F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J. Neurosci, 1986, 6(8), 2155-2162.
71. Tuszynski, M.H.; Thal, L.; Pay, M.; Salmon, D.P.; U, H.S.; Bakay, R.; Patel, P.; Blesch, A.; Vahlsing, H.L.; Ho, G.; Tong, G.; Potkin, S.G.; Fallon, J.; Hansen, L.; Mufson, E.J.; Kordower, J.H.; Gall, C.; Conner, J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med., 2005, 11(5), 551-555.
72. Lapchak, P.A.; Araujo, D.M.; Carswell, S.; Hefti, F. Distribution of [125I]nerve growth factor in the rat brain following a single intraventricular injection: correlation with the topographical distribution of trkA messenger RNA-expressing cells. Neuroscience, 1993, 54(2), 445-460.
73. Eide, F.F.; Lowenstein, D.H.; Reichardt, L.F., Neurotrophins and their receptors--current concepts and implications for neurologic disease. Exp. Neurol., 1993, 121(2), 200-214.
74. Montero, C.N.; Hefti, F. Rescue of lesioned septal cholinergic neurons by nerve growth factor: specificity and requirement for chronic treatment. J. Neurosci., 1988, 8(8), 2986-2999.
75. Niewiadomska, G.; Komorowski, S.; Baksalerska-Pazera, M. Amelioration of cholinergic neurons dysfunction in aged rats depends on the continuous supply of NGF. Neurobiol. Aging., 2002, 23(4), 601-613.
76. Benoit, J.P.; Faisant, N.; Venier-Julienne, M.C.; Menei, P. Development of microspheres for neurological disorders: from basics to clinical applications. J. Control. Release, 2000, 65(1-2), 285-296.
77. Yamamoto, S.; Yoshimine, T.; Fujita, T.; Kuroda, R.; Irie, T.; Fujioka, K.; Hayakawa, T. Protective effect of NGF atelocollagen mini-pellet on the hippocampal delayed neuronal death in gerbils. Neurosci. Lett., 1992, 141(2), 161-165.
78. Powell, E.M.; Sobarzo, M.R.; Saltzman, W.M. Controlled release of nerve growth factor from a polymeric implant. Brain Res., 1990, 515(1-2), 309-311.
79. Krewson, C.E.; Klarman, M.L.; Saltzman, W.M. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res., 1995, 680(1-2), 196-206.
80. Hoffman, D.; Wahlberg, L.; Aebischer, P. NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria-fornix lesion. Exp. Neurol., 1990, 110(1), 39-44.
81. Cleland, J.L.; Barron, L.; Berman, P.W.; Daugherty, A.; Gregory, T.; Lim, A.; Vennari, J.; Wrin, T.; Powell, M.F. Development of a single-shot subunit vaccine for HIV-1. 2. Defining optimal autoboost characteristics to maximize the humoral immune response. J Pharm. Sci., 1996, 85(12), 1346-1349.
82. Camarata, P.J.; Suryanarayanan, R.; Turner, D.A.; Parker, R.G.; Ebner, T.J. Sustained release of nerve growth factor from biodegradable polymer microspheres. Neurosurgery, 1992, 30(3), 313-319.
83. Mendez, A.C., P.J.; Suryanarayanan, R.; Ebner, T.J. Sustained intracerebral delivery of nerve growth factor with biodegradable polymer microspheres. Methods Neurosci., 1994, 21, 150-167.
84. Krewson, C.E.; Dause, R.; Mak, M.; Saltzman, W.M. Stabilization of nerve growth factor in controlled release polymers and in tissue. J. Biomater. Sci. Polym. Ed., 1996, 8(2), 103-117.
85. Maysinger, D.; Filipovic-Grcic, J.; Cuello, A.C. Effects of coencapsulated NGF and GM1 in rats with cortical lesions. Neuroreport., 1993, 4(7), 971-974.
86. Pean, J.M. V.-J., M.C.; Filmon. R.; Sergent, M.; Phan-Tan-Luuc, R.; Benoit, J.P. Optimization of HSA and NGF encapsulation yields in PLGA microparticles. Int. J. Pharm., 1998, 166(1), 105-115.
87. Pean, J.M.; Boury, F.; Venier-Julienne, M.C.; Menei, P.; Proust, J.E.; Benoit, J.P. Why does PEG 400 co-encapsulation improve NGF stability and release from PLGA biodegradable microspheres? Pharm. Res., 1999, 16(8), 1294-1299.
88. Pean, J.M.; Venier-Julienne, M.C.; Boury, F.; Menei, P.; Denizot, B.; Benoit, J.P. NGF release from poly(D, L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability. J. Control. Release, 1998, 56(1-3), 175-187.
89. Pean, J.M.; Menei, P.; Morel, O.; Montero-Menei, C.N.; Benoit, J.P. Intraseptal implantation of NGF-releasing microspheres promote the survival of axotomized cholinergic neurons. Biomaterials, 2000, 21(20), 2097-2101.
90. Gu, H.; Long, D.; Song, C.; Li, X. Recombinant human NGFloaded microspheres promote survival of basal forebrain cholinergic neurons and improve memory impairments of spatial learning in the rat model of Alzheimer's disease with fimbria-fornix lesion. Neurosci. Lett., 2009, 453(3), 204-209.
91. Gu, H.S., C.; Long, D.; Mei, L.; Sun, H. Controlled release of recombinant human nerve growth factor (rhNGF) from poly[(lactic acid)-co-(glycolic acid)] microspheres for the treament of neurodegenerative disorders. Polymer Intl., 2007, 56(10), 1272-1280.
92. Reichman, W.E. Current pharmacologic options for patients with Alzheimer's disease. Ann. Gen. Hosp. Psychiatry, 2003, 2, (1), 1.
93. Jogani, V.V.; Shah, P.J.; Mishra, P.; Mishra, A.K.; Misra, A.R. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis. Assoc. Disord., 2008, 22(2), 116-124.
94. Wilson, B.; Samanta, M.K.; Santhi, K.; Sampath Kumar, K.P.; Ramasamy, M.; Suresh, B. Significant delivery of tacrine into the brain using magnetic chitosan microparticles for treating Alzheimer's disease. J. Neurosci. Methods, 2009, 177(2), 427-433.
95. Gupta, P.K.; Hung, C.T. Magnetically controlled targeted microcarrier systems. Life Sci., 1989, 44(3), 175-186.
96. Wilson, B.; Samanta, M.K.; Santhi, K.; Kumar, K.P.; Paramakrishnan, N.; Suresh, B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res., 2008, 1200, 159-168.
97. Nordberg, A.; Svensson, A.L. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf., 1998, 19(6), 465-480.
98. Weinstock, M. Selectivity of cholinesterase inhibition. clinical ilications for the treatment of Alzheimer's disease. CNS Drugs, 1999, 12, 307-323.
99. Jann, M.W.; Shirley, K.L.; Small, G.W. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin. Pharmacokinet., 2002, 41(10), 719-739.
100. Kreuter, J.; Shamenkov, D.; Petrov, V.; Ramge, P.; Cychutek, K.; Koch-Brandt, C.; Alyautdin, R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target, 2002, 10(4), 317-325.
101. Yang, Z.; Zhang, Y.; Yang, Y.; Sun, L.; Han, D.; Li, H.; Wang, C. Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease. Nanomedicine., 2010, 6(3),427-441.
102. Brayden, D.J.; Templeton, L.; McClean, S.; Barbour, R.; Huang, J.; Nguyen, M.; Ahern, D.; Motter, R.; Johnson-Wood, K.; Vasquez, N.; Schenk, D.; Seubert, P. Encapsulation in biodegradable microparticles enhances serum antibody response to parenterallydelivered beta-amyloid in mice. Vaccine, 2001, 19(30), 4185-4193.
103. Rajkannan, R.; Arul, V.; Malar, E.J.; Jayakumar, R. Preparation, physiochemical characterization, and oral immunogenicity of Abeta(1-12), Abeta(29-40), and Abeta(1-42) loaded PLG microparticles formulations. J. Pharm. Sci., 2009, 98(6), 2027-2039.
104. Conway, M.A.; Madrigal-Estebas, L.; Mc Clean, S.; Brayden, D.J.; Mills, K.H. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine, 2001, 19(15-16), 1940-1950.
105. De Magistris, M.T. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv. Drug Deliv. Rev., 2006, 58(1), 52-67.
106. Songjiang, Z.; Lixiang, W. Amyloid-beta associated with chitosan nano-carrier has favorable immunogenicity and permeates the BBB. AAPS PharmSciTech., 2009, 10(3), 900-905.
107. Nicolau, C.; Greferath, R.; Balaban, T.S.; Lazarte, J.E.; Hopkins, R.J. A liposome-based therapeutic vaccine against beta-amyloid plaques on the pancreas of transgenic NORBA mice. Proc. Natl. Acad. Sci. USA, 2002, 99(4), 2332-2337.
108. Muhs, A.; Hickman, D.T.; Pihlgren, M.; Chuard, N.; Giriens, V.; Meerschman, C.; van der Auwera, I.; van Leuven, F.; Sugawara, M.; Weingertner, M.C.; Bechinger, B.; Greferath, R.; Kolonko, N.; Nagel-Steger, L.; Riesner, D.; Brady, R.O.; Pfeifer, A.; Nicolau, C. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc. Natl. Acad. Sci. USA, 2007, 104(23), 9810-9815.
109. Ikeda, K.; Okada, T.; Sawada, S.; Akiyoshi, K.; Matsuzaki, K. Inhibition of the formation of amyloid beta-protein fibrils using biocompatible nanogels as artificial chaperones. FEBS Lett., 2006, 580(28-29), 6587-6595.
110. Nomura, Y.; Ikeda, M.; Yamaguchi, N.; Aoyama, Y.; Akiyoshi, K. Protein refolding assisted by self-assembled nanogels as novel artificial molecular chaperone. FEBS Lett., 2003, 553(3), 271-276.
111. Modi, G.; Pillay, V.; Choonara, Y.E.; Ndesendo, V.M.; du Toit, L.C.; Naidoo, D. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog. Neurobiol., 2009, 88(4), 272-285.
112. listed, N. a. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's disease collaborative research group. Cell, 1993, 72(6), 971-983.
113. Frim, D.M.; Yee, W.M.; Isacson, O. NGF reduces striatal excitotoxic neuronal loss without affecting concurrent neuronal stress. Neuroreport., 1993, 4(6), 655-658.
114. Frim, D.M.; Uhler, T.A.; Short, M.P.; Ezzedine, Z.D.; Klagsbrun, M.; Breakefield, X. O.; Isacson, O. Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. Neuroreport., 1993, 4 (4), 367-370.
115. Frim, D.M.; Short, M.P.; Rosenberg, W.S.; Simpson, J.; Breakefield, X.O.; Isacson, O. Local protective effects of nerve growth factor-secreting fibroblasts against excitotoxic lesions in the rat striatum. J. Neurosurg., 1993, 78(2), 267-273.
116. Kordower, J.H.; Charles, V.; Bayer, R.; Bartus, R.T.; Putney, S.; Walus, L.R.; Friden, P.M. Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease. Proc. Natl. Acad. Sci. USA, 1994, 91(19), 9077-9080.
117. Kordower, J.H.; Chen, E.Y.; Mufson, E.J.; Winn, S.R.; Emerich, D.F. Intrastriatal implants of polymer encapsulated cells genetically modified to secrete human nerve growth factor: trophic effects upon cholinergic and noncholinergic striatal neurons. Neuroscience, 1996, 72(1), 63-77.
118. Martinez-Serrano, A.; Bjorklund, A. Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. J. Neurosci., 1996, 16(15), 4604-4616.
119. Beal, M. F.; Kowall, N. W.; Ellison, D. W.; Mazurek, M. F.; Swartz, K. J.; Martin, J. B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature, 1986, 321(6066), 168-171.
120. Beal, M.F.; Ferrante, R.J.; Swartz, K.J.; Kowall, N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci., 1991, 11(6), 1649-1659.
121. Menei, P.; Pean, J.M.; Nerriere-Daguin, V.; Jollivet, C.; Brachet, P.; Benoit, J.P. Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage. Exp. Neurol., 2000, 161(1), 259-272.
122. Hagg, T.; Quon, D.; Higaki, J.; Varon, S. Ciliary neurotrophic factor prevents neuronal degeneration and promotes low affinity NGF receptor expression in the adult rat CNS. Neuron., 1992, 8(1), 145-158.
123. Hagg, T.; Varon, S. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc. Natl. Acad. Sci. USA, 1993, 90(13), 6315-6319.
124. Anderson, K.D.; Panayotatos, N.; Corcoran, T.L.; Lindsay, R.M.; Wiegand, S.J. Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. Proc. Natl. Acad. Sci. USA, 1996, 93(14), 7346-7351.
125. Clatterbuck, R.E.; Price, D.L.; Koliatsos, V.E. Ciliary neurotrophic factor prevents retrograde neuronal death in the adult central nervous system. Proc. Natl. Acad. Sci. USA, 1993, 90(6), 2222-2226.
126. Maysinger, D.; Krieglstein, K.; Filipovic-Grcic, J.; Sendtner, M.; Unsicker, K.; Richardson, P. Microencapsulated ciliary neurotrophic factor: physical properties and biological activities. Exp. Neurol., 1996, 138(2), 177-188.
127. Emerich, D.F.; Lindner, M.D.; Winn, S.R.; Chen, E.Y.; Frydel, B.R.; Kordower, J.H. Implants of encapsulated human CNTFproducing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J. Neurosci., 1996, 16(16), 5168-5181.
128. Emerich, D.F.; Winn, S.R.; Hantraye, P.M.; Peschanski, M.; Chen, E.Y.; Chu, Y.; McDermott, P.; Baetge, E.E.; Kordower, J.H. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature, 1997, 386(6623), 395-399.
129. Bloch, J.; Bachoud-Levi, A.C.; Deglon, N.; Lefaucheur, J.P.; Winkel, L.; Palfi, S.; Nguyen, J.P.; Bourdet, C.; Gaura, V.; Remy, P.; Brugieres, P.; Boisse, M.F.; Baudic, S.; Cesaro, P.; Hantraye, P.; Aebischer, P.; Peschanski, M. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum. Gene Ther., 2004, 15(10), 968-975.
130. Mittal, S.; Cohen, A.; Maysinger, D. In vitro effects of brain derived neurotrophic factor released from microspheres. Neuroreport., 1994, 5(18), 2577-2582.
131. Koennings, S.; Sapin, A.; Blunk, T.; Menei, P.; Goepferich, A. Towards controlled release of BDNF--manufacturing strategies for protein-loaded lipid implants and biocompatibility evaluation in the brain. J. Control. Release, 2007, 119(2), 163-172.
132. Hao, X.; Silva, E.A.; Mansson-Broberg, A.; Grinnemo, K.H.; Siddiqui, A.J.; Dellgren, G.; Wardell, E.; Brodin, L. A.; Mooney, D.J.; Sylven, C. Angiogenic effects of sequential release of VEGFA165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc. Res., 2007, 75(1), 178-185.
133. Silva, E.A.; Mooney, D.J. Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J. Thromb. Haemost., 2007, 5(3), 590-598.
134. Emerich, D.F.; Mooney, D.J.; Storrie, H.; Babu, R.S.; Kordower, J.H. Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease. Neurotox. Res., 2010, 17(1), 66-74.